Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Clin Exp Pharmacol Physiol ; 45(2): 155-165, 2018 02.
Article in English | MEDLINE | ID: mdl-28949404

ABSTRACT

Spleen tyrosine kinase (Syk), a non-receptor tyrosine kinase, plays an important role in allergic diseases and inflammation. Syk triggers several intracellular signalling cascades including Toll-like receptor signalling to activate inflammatory responses following fungal infection but the role of this enzyme in zymosan (ZYM)-induced non-septic shock and its impacts on hypotension and inflammation in rats is not well understood. This study was conducted to determine the effects of Syk inhibition on ZYM-induced alterations in the expression and/or activities of Syk, inhibitor ĸB (IĸB)-α, and nuclear factor-ĸB (NF-ĸB) p65. We also examined the effect of Syk inhibition on inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and tumour necrosis factor (TNF)-α, and activity of myeloperoxidase (MPO) that contribute to hypotension and inflammation. Administration of ZYM (500 mg/kg, ip) to male Wistar rats decreased blood pressure and increased heart rate. These changes were associated with increased expression and/or activities of Syk, NF-κB p65, iNOS and COX-2 and decreased expression of IκB-α with enhanced levels of nitrite, nitrotyrosine, 6-keto-PGF1α , and TNF-α and activity of MPO in renal, cardiac and vascular tissues. ZYM administration also elevated serum and tissue nitrite levels. The selective Syk inhibitor BAY 61-3606 (3 mg/kg, ip) given 1 hour after ZYM injection reversed all of these changes induced by ZYM. These results suggest that Syk/IĸB-α/NF-ĸB pathway activation contributes to hypotension and inflammation caused by the production of vasodilator and proinflammatory mediators in the zymosan-induced non-septic shock model.


Subject(s)
I-kappa B Kinase/metabolism , NF-kappa B/metabolism , Niacinamide/analogs & derivatives , Pyrimidines/therapeutic use , Shock/chemically induced , Syk Kinase/metabolism , Animals , Gene Expression Regulation/drug effects , I-kappa B Kinase/genetics , Male , NF-kappa B/genetics , Niacinamide/therapeutic use , Rats , Rats, Wistar , Shock/drug therapy , Syk Kinase/antagonists & inhibitors , Syk Kinase/genetics , Zymosan/toxicity
2.
Inflammation ; 41(1): 337-355, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29188497

ABSTRACT

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that can activate or inhibit the expression of many target genes by forming a heterodimer complex with the retinoid X receptor (RXR). The aim of this study was to investigate effects of bexarotene, a selective RXRα agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARα/ß/γ-RXRα heterodimer formation in a rat model of septic shock. Rats were injected with dimethyl sulfoxide or bexarotene 1 h after administration of saline or lipopolysaccharide (LPS). Mean arterial pressure (MAP) and heart rate (HR) were recorded from rats, which had received either saline or LPS before and after 1, 2, 3, and 4 h. Serum iNOS, LTB4, myeloperoxidase (MPO), and lactate dehydrogenase (LDH) levels as well as tissue iNOS and CYP4F6 mRNA expression in addition to PPARα/ß/γ and RXRα proteins were measured. LPS-induced decrease in MAP and increase in HR were associated with a decrease in PPARα/ß/γ-RXRα heterodimer formation and CYP4F6 mRNA expression. LPS also caused an increase in systemic iNOS, LTB4, MPO, and LDH levels as well as iNOS mRNA expression. Bexarotene at 0.1 mg/kg (i.p.) prevented the LPS-induced changes, except tachycardia. The results suggest that increased formation of PPARα/ß/γ-RXRα heterodimers and CYP4F6 expression/activity in addition to decreased iNOS expression contributes to the beneficial effect of bexarotene to prevent the hypotension associated with inflammation and tissue injury during rat endotoxemia.


Subject(s)
Arterial Pressure/drug effects , Hypotension/prevention & control , Inflammation/drug therapy , Retinoid X Receptor alpha/agonists , Shock, Septic/drug therapy , Tetrahydronaphthalenes/pharmacology , Animals , Bexarotene , Cytochrome P450 Family 4/genetics , Cytochrome P450 Family 4/metabolism , Disease Models, Animal , Heart Rate/drug effects , Hypotension/chemically induced , Hypotension/metabolism , Hypotension/physiopathology , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/physiopathology , Kidney/drug effects , Kidney/metabolism , L-Lactate Dehydrogenase/blood , Leukotriene B4/blood , Lipopolysaccharides , Liver/drug effects , Liver/metabolism , Lung/drug effects , Lung/metabolism , Male , Multiprotein Complexes , Myocardium/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Peroxidase/blood , Peroxisome Proliferator-Activated Receptors/metabolism , Rats, Wistar , Retinoid X Receptor alpha/metabolism , Shock, Septic/chemically induced , Shock, Septic/metabolism , Shock, Septic/physiopathology , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL